Dose-response study with high-dose inhaled salmeterol in healthy subjects.
A double-blind, placebo-controlled, cross-over study in 10 healthy male subjects has been carried out to investigate the non-pulmonary effects of single inhaled doses of salmeterol 100 micrograms, 200 micrograms and 400 micrograms and salbutamol 400 micrograms from a metered-dose inhaler. At all doses tested, salmeterol produced statistically significant changes in pulse rate, tremor, blood glucose and plasma potassium concentrations, compared with placebo. All changes were dosed related. A number of dose-related adverse events including tremor, awareness of heart beat and headache were reported after salmeterol administration.
Department of Clinical Pharmacology, Glaxo Group Research Limited, Greenford, Middlesex.
J G
JG
Maconochie
J K
JK
Forster
D000280:Administration, Inhalation; D000318:Adrenergic beta-Agonists / Q000494:pharmacology*; D000328:Adult; D000420:Albuterol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D001786:Blood Glucose / Q000032:analysis; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D006801:Humans; D008297:Male; D010919:Placebos; D011188:Potassium / Q000032:analysis; D012016:Reference Values; D000068299:Salmeterol Xinafoate
D000318:Adrenergic beta-Agonists; D001786:Blood Glucose; D010919:Placebos; D000068299:Salmeterol Xinafoate; D000420:Albuterol; D011188:Potassium